MENU News OSIVAX AND 3P BIOPHARMACEUTICALS TEAM UP TO DEVELOP A NEW UNIVERSAL VACCINE AGAINST CURRENT AND FUTURE VARIANTS OF SARS-COV-2 Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19 READ MORE ELENA ERROBA, WINNER OF THE NAVARRA 2021 MANAGEMENT AWARD ORGANISED BY AMEDNA-NEEZE Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021 READ MORE 3P BIOPHARMACEUTICALS PRESENTS ITS GROWTH PLAN AT BIOSPAIN TO FURTHER EXPAND ITS OPERATIONS IN EUROPE AND THE USA The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple. READ MORE 3P BIOPHARMACEUTICALS APPOINTS DIEGO BOCHOEYER AS DIRECTOR OF STRATEGIC DEVELOPMENT AND SUPPLY CHAIN 3P Biopharmaceuticals incorporates a new member to the executive management team by engaging Diego Bochoeyer as Director of Strategic Development and Supply Chain. READ MORE 3P BIOPHARMACEUTICALS ENTERS INTO ALLIANCE WITH PRECIRIX TO DEVELOP PRECISION RADIOPHARMACEUTICALS IN ONCOLOGY 3P Biopharmaceuticals and Precirix NV have signed an agreement for the clinical manufacturing of a camelid single-domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic. READ MORE 3P BIOPHARMACEUTICALS RECEIVES FDA APPROVAL The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized READ MORE 3P BIOPHARMACEUTICALS REINFORCES ITS COMMITMENT TO FEMALE TALENT WITH ITS PARTICIPATION IN THE PROGRAMME ‘LIDERA EN FEMENINO-STEM’ The Head of Quality Assurance & Qualified Person at 3P Biopharmaceuticals, Susana Santesteban, has attended ‘Lidera en femenino-STEM’, a course that aims to help promote the career advancement of STEM women. READ MORE 3P BIOPHARMACEUTICALS AND BUZZARD PHARMACEUTICALS START A CGMP MANUFACTURING COLLABORATION TO DEVELOP A NEW TREATMENT TO COMBAT SOLID TUMOURS 3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for cGMP manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications. READ MORE WORKING IN BIOTECHNOLOGY MEANS WORKING TO IMPROVE THE PLANET AND PEOPLE’S LIVES Ion Arocena, CEO of AseBio, has delivered a speech at an event organised as part of the agreement that 3P Biopharmaceuticals has signed with the School of Pharmacy and Nutrition of the University of Navarra to promote training in Biotechnology READ MORE 1 2 3 4 Older Posts Get in touch Let’s discuss your biologics journey. Discover more about our people, our passion, and how we can work together to improve lives. ENQUIRE HERE ITSWITHINUS@3PBIO.COM +34 948 346 480 Company About us Our Story Our responsibility Leadership team Services Overview Mammalian Services Microbial Services Cell Therapy Careers Current opportunities Send your CV Learning & Development Meet Our People Navarra, a place to stay Resources News Events Privacy Policy Cookie Policy Legal Notice © 2021 3P Biopharmaceuticals. All rights reserved Esta empresa ha recibido una ayuda cofinanciada al 50% por el Fondo Europeo de Desarrollo Regional a través del Programa Operativo FEDER 2014-2020 de Navarra